{"id":"NCT03480763","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-22","primaryCompletion":"2019-12-23","completion":"2019-12-23","firstPosted":"2018-03-29","resultsPosted":"2021-01-06","lastUpdate":"2021-11-02"},"enrollment":652,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V114","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevnar 13™","otherNames":["PCV13"]},{"type":"BIOLOGICAL","name":"PNEUMOVAX™23","otherNames":["PPV23"]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"},{"label":"Prevnar 13™","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed 1) to evaluate the safety, tolerability, and immunogenicity of V114 and Prevnar 13™, 2) to describe the safety of sequential administration of V114 or Prevnar 13™ followed by PNEUMOVAX™23, and 3) to evaluate the immune responses to the 15 serotypes contained in V114 when PNEUMOVAX™23 is given approximately 12 months after receipt of either V114 or Prevnar 13™ in healthy adults 50 years of age or older. There was no formal hypothesis testing.","primaryOutcome":{"measure":"Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™","timeFrame":"Up to 5 days after Vaccination 1","effectByArm":[{"arm":"V114","deltaMin":9.8,"sd":null},{"arm":"Prevnar 13™","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.043"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"0.077"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":22,"countries":["United States","South Korea","Spain","Taiwan"]},"refs":{"pmids":["34489128","40537903"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":327},"commonTop":["Injection site pain","Fatigue","Injection site swelling","Myalgia","Injection site erythema"]}}